Hellerhoff, Inger
King, Joseph A. http://orcid.org/0000-0002-2864-5578
Tam, Friederike I. http://orcid.org/0000-0001-8333-867X
Pauligk, Sophie
Seidel, Maria
Geisler, Daniel http://orcid.org/0000-0003-2076-5329
Bahnsen, Klaas http://orcid.org/0000-0002-5413-0359
Kretschmann, Nicole
Akgün, Katja
Roessner, Veit
Ziemssen, Tjalf
Ehrlich, Stefan http://orcid.org/0000-0003-2132-4445
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (EH 367/5-1, EH 367/7-1, SFB 940/2, EH 367/5-1, EH 367/7-1, SFB 940/2, EH 367/5-1, EH 367/7-1, SFB 940/2, EH 367/5-1, EH 367/7-1, SFB 940/2, EH 367/5-1, EH 367/7-1, SFB 940/2, EH 367/5-1, EH 367/7-1, SFB 940/2, EH 367/5-1, EH 367/7-1, SFB 940/2, EH 367/5-1, EH 367/7-1, SFB 940/2)
Swiss Anorexia Nervosa Foundation, B. Braun Foundation
Article History
Received: 15 May 2020
Revised: 8 December 2020
Accepted: 11 December 2020
First Online: 9 February 2021
Conflict of interest
: I. Hellerhoff, J. A. King, F. I. Tam, S. Pauligk, M. Seidel, D. Geisler, K. Bahnsen, N. Kretschmann, and S. Ehrlich declare no competing interests. K. Akgün received honoraria for presentations/advisory boards from Biogen Idec, Merck, Sanofi, and Roche. V. Roessner has received payment for consulting and writing activities from Lilly, Novartis, and Shire Pharmaceuticals, lecture honoraria from Lilly, Novartis, Shire Pharmaceuticals, and Medice Pharma, and support for research from Shire and Novartis. He has carried out (and is currently carrying out) clinical trials in cooperation with the Novartis, Shire, and Otsuka companies. T. Ziemssen received personal compensation from Almirall, Biogen Idec, Bayer, Celgene, Novartis, Roche, Sanofi, Teva for consulting services. He received additional financial support for research activities from BAT, Biogen, Novartis, Roche, Teva, and Sanofi Aventis. Funding sources were not involved in the design of the study, the collection and analysis of data, or the decision to publish.